MedPath

Single arm non-randomized study for Androgenetic Alopecia.

Not Applicable
Not yet recruiting
Conditions
Health Condition 1: L649- Androgenic alopecia, unspecified
Registration Number
CTRI/2022/12/047935
Lead Sponsor
A
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients clinically diagnosed with of AGA

2.Age: 18-60 years,

3.Either sex

4.Not on topical minoxidil or other pharmacological treatments that could affect the result

Exclusion Criteria

1.Patient with hypertension, migraine, head injury, mental disorder, scalp infection, epilepsy, stroke

2.Oral treatment to the hair loss within six months

3.Pregnancy and lactation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To determine the safety and the efficacy of the Mesojet system in treatment of androgenetic alopeciaTimepoint: After 4 months
Secondary Outcome Measures
NameTimeMethod
Hair density will be assessed <br/ ><br>and analysed with the help of <br/ ><br>trichoscan as well as global <br/ ><br>photographs by comparison <br/ ><br>between baseline and 16 weeksTimepoint: after 4 months
© Copyright 2025. All Rights Reserved by MedPath